Axoft Secures $55M Series A to Advance Clinical Trials Globally for its Bio-Inspired, Implantable Brain-Computer Interface
Powered by the company’s novel Fleuron™ material, Axoft’s iBCI platform enables unprecedented biocompatibility and high quality neural data capture with successful implantation in 11 patients to date. CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axoft, a neurotechnology company, today announced…